A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Sponsors Biogen; Ionis Pharmaceuticals
- 06 Nov 2017 Status changed from active, no longer recruiting to completed.
- 28 Jul 2017 Planned End Date changed from 1 Jun 2017 to 31 Aug 2017.
- 28 Jul 2017 Planned primary completion date changed from 1 May 2017 to 31 Aug 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History